Pharmacotherapy of atrial fibrillation.
Atrial fibrillation (AF) remains a widespread health problem and the drugs available for its treatment suffer from several drawbacks, including potentially lethal proarrhythmia, serious non-cardiac toxicity and limited efficacy. The evidence for efficacy of currently available anti-arrhythmic agents for sinus rhythm restoration and maintenance is reviewed, with emphasis on randomised trials when available. The current approach to thromboembolism prophylaxis in AF is summarised.
Nemec
J
J
Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA.
Shen
W K
WK
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans
D000889:Anti-Arrhythmia Agents; D002317:Cardiovascular Agents